Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data
| Image |  |
|---|---|
| Description | scientific article published on 24 July 2019 |
| Author/s | |
| Publication date | July 24, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |